PubMed:10411803 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":249,"end":265},"obj":"HP_0001878"},{"id":"T2","span":{"begin":259,"end":265},"obj":"HP_0001903"},{"id":"T3","span":{"begin":323,"end":340},"obj":"HP_0001878"},{"id":"T4","span":{"begin":333,"end":340},"obj":"HP_0001903"},{"id":"T5","span":{"begin":482,"end":498},"obj":"HP_0001878"},{"id":"T6","span":{"begin":492,"end":498},"obj":"HP_0001903"}],"text":"Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.\nSecond- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia. We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures. Eight of these cases of severe immune hemolytic anemia are described."}

{"project":"PubCasesHPO","denotations":[{"id":"TI1","span":{"begin":14,"end":30},"obj":"HP:0001878"},{"id":"AB1","span":{"begin":249,"end":265},"obj":"HP:0001878"},{"id":"AB2","span":{"begin":323,"end":340},"obj":"HP:0001878"},{"id":"AB3","span":{"begin":482,"end":498},"obj":"HP:0001878"}],"text":"Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.\nSecond- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia. We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures. Eight of these cases of severe immune hemolytic anemia are described."}

{"project":"bc5cdr-valid-experiment","denotations":[{"id":"T1","span":{"begin":14,"end":30},"obj":"Disease"},{"id":"T2","span":{"begin":67,"end":76},"obj":"Chemical"},{"id":"T3","span":{"begin":147,"end":161},"obj":"Chemical"},{"id":"T4","span":{"begin":174,"end":183},"obj":"Chemical"},{"id":"T5","span":{"begin":249,"end":265},"obj":"Disease"},{"id":"T6","span":{"begin":305,"end":314},"obj":"Chemical"},{"id":"T7","span":{"begin":323,"end":340},"obj":"Disease"},{"id":"T8","span":{"begin":375,"end":384},"obj":"Chemical"},{"id":"T9","span":{"begin":482,"end":498},"obj":"Disease"}],"text":"Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.\nSecond- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia. We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures. Eight of these cases of severe immune hemolytic anemia are described."}